Q4 2024 Globus Medical Inc Earnings Call Transcript
Key Points
- Globus Medical Inc (GMED) achieved record sales in 2024 with revenue reaching $2.519 billion, marking a 61% increase compared to the previous year.
- The company reported a significant increase in non-GAAP EPS, reaching $3.04, which is a 31% rise despite a 20% increase in diluted shares.
- Free cash flow reached an all-time high of $405 million, a 145% increase from the prior year, enabling the company to return to a debt-free status by Q1 2025.
- Globus Medical Inc (GMED) launched 18 new products in 2024, showcasing its commitment to innovation and market leadership.
- The company reported strong growth in its enabling technology sales, with a 44% increase in Q4 and a 47% growth in unit placements compared to the prior year.
- The company faced a temporary supply chain disruption in its trauma and NSO business, which is expected to be resolved in Q1 2025.
- There was a $0.10 headwind to non-GAAP EPS and a 0.72% unfavorable impact to adjusted EBITDA due to foreign currency loss.
- Gross profit for the full year 2024 declined to 55.6% from 64.1% in the prior year, primarily due to higher product costs and inventory step-up amortization.
- The acquisition of Nevro Corporation, while expanding market reach, is subject to shareholder and regulatory approval, introducing potential uncertainty.
- The company anticipates a modest improvement in gross margin for 2025, with significant expansion expected only in 2026 as in-sourcing efforts take shape.
Welcome to the Globus Medical's fourth-quarter and full year 2024 earnings call. (Operator Instructions) I will now turn the call over to Brian Kearns, Senior Vice President of Business Development and Investor relations. Mr. Kearns, please go ahead.
Thank you, [Didi], and thank you, everyone, for being with us today. Joining today's call from Globus Medical will be Dan Scavilla, President and CEO; and Keith Pfeil, Chief Operating and Chief Financial Officer. This review is being made available via webcast accessible through the Investor Relations section of the Globus Medical website at www.globusmedical.com.
Before we begin, let me remind you that some of the statements made during this review are or may be considered forward-looking statements. Our Form 10-K for the 2024 fiscal year and our subsequent filings with the Securities and Exchange Commission identified certain factors that could cause our actual results to differ
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
